Cynapsus Therapeutics Inc  

(Public, CVE:CTH)   Watch this stock  
Find more results for CTH
1.24
Nov 27 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 0.38 - 1.51
Open     -
Vol / Avg. 0.00/303,419.00
Mkt cap 98.66M
P/E     -
Div/yield     -
EPS -0.14
Shares 79.56M
Beta 0.81
Inst. own     -
Nov 9, 2015
Q3 2015 Results Add to calendar
Nov 9, 2015
Q3 2015 Cynapsus Therapeutics Inc Earnings Release (Estimated) Add to calendar
Sep 10, 2015
Cynapsus Therapeutics Inc at BioCentury NewsMakers in the Biotech Industry Conference - 1:30PM EDT - Add to calendar
Sep 9, 2015
Cynapsus Therapeutics Inc at Rodman & Renshaw Global Investment Conference - 11:15AM EDT - Add to calendar
Aug 14, 2015
Q2 2015 Cynapsus Therapeutics Inc Earnings Release
Aug 7, 2015
Q2 2015 Results
Jun 20, 2015
European Academy of Neurology (EAN) Meeting Presentation
Jun 14, 2015
International Congress of Parkinson's Disease and Movement Disorders Society (MDS) Presentation
  

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -58.07% -99.71%
Return on average equity -60.84% -134.69%
Employees 6 -
CDP Score - -

Address

828 Richmond St W
TORONTO, ON M6J 1C9
Canada
+1-416-7032449 (Phone)
+1-416-7038752 (Fax)

Website links

Description

Cynapsus Therapeutics Inc. is a Canada-based clinical-stage, specialty pharmaceutical company. The Company is engaged in developing a sublingual thin filmstrip to manage OFF episodes associated with Parkinson’s disease. The Company's drug candidate is APL-130277, which is a reformulation of apomorphine. The drug is an approved acute drug in the United States, Europe, Japan and other countries. The Company completed a CTH-105 Phase II clinical trial comprising approximately 16 people with Parkinson's disease.

Officers and directors

Rochelle E. Stenzler Independent Chairman of the Board
Age: 52
Anthony Giovinazzo President, Chief Executive Officer, Director
Andrew Williams Chief Financial Officer, Chief Operating Officer
Thierry Bilbault Executive Vice President - Chemistry, Manufacturing and Controls, Chief Scientific Officer
Jordan Dubow M.D. Vice President - Medical Affairs
Albert Agro Chief Medical Officer
Tomer Gold Independent Director
Ronald G. Hosking Independent Director
Age: 70
Tamar D. Howson Independent Director
Age: 66
Nan Hutchinson Independent Director